Body size alone shouldn't rule out nutrition risk. Food intake, pace of weight loss, strength, and mobility tell a more complete story than the scale does.
That's because a person can be overweight and still be malnourished. It seems contradictory, but body weight alone doesn't show whether someone is getting the protein, vitamins, and minerals needed to maintain health and physical function.
That distinction matters more as GLP-1 medications, including semaglutide and tirzepatide, become mainstream weight-loss tools. These drugs sharply reduce appetite and food intake, but eating less raises the stakes on what a person does eat.
During Malnutrition Awareness Week, led by the American Society for Parenteral and Enteral Nutrition, health care professionals, patients and caregivers are encouraged to question a common assumption: that malnutrition affects only people who look thin. It doesn't. Malnutrition happens when the body doesn't get or absorb enough nutrients, whether from eating too little, illness or an unbalanced diet, and it can affect people of any body size. Someone can carry excess weight while getting too little protein or too few vitamins and minerals, or lose weight on purpose while dealing with nutritional problems the scale doesn't reveal.
GLP-1 medications reduce appetite, increase fullness, and slow digestion. Those same mechanisms that make them effective can also make it harder to eat enough, especially for people dealing with nausea, vomiting or constipation.
A 2026 review in the Journal of Nutrition found that the rapid adoption of GLP-1 therapies has outpaced the nutrition support built around them, and that sharp reductions in food intake can raise the risk of inadequate protein, fiber, fluid, and micronutrient intake, along with loss of lean tissue. Proper assessment and monitoring can address much of that risk, which is why nutrition care belongs in treatment from the start.
Significant weight loss almost always includes some loss of lean tissue along with fat. A 2026 meta-analysis of 20 randomized controlled trials, covering nearly 16,000 participants, found that lean mass made up a meaningful share of weight lost with incretin-based therapies(also known as GLP-1 medications), similar to what's seen with intensive lifestyle-based weight loss, and that resistance training helped preserve more of it. In the SEMALEAN study, lean mass in adults taking semaglutide declined early and then stabilized, while handgrip strength improved over 12 months. Losing some lean mass doesn't automatically mean a person is getting weaker.
People taking GLP-1 medications, and those caring for them, should watch for:
Eating much less than usual or skipping meals regularly
Feeling full after only a few bites
Persistent nausea or vomiting that interferes with eating or drinking
Trouble getting enough protein or variety in the diet
Unintended or unusually rapid weight loss
New or worsening fatigue, weakness or loss of stamina
Trouble getting up from a chair, climbing stairs or completing daily tasks
Dizziness or other signs of dehydration
A noticeable decline in strength, mobility or independence
None of these signs necessarily mean someone is malnourished, and none mean a medication should be stopped, a decision that belongs with the prescribing clinician. What they do is start a conversation with a physician or dietitian, who can evaluate food intake and history to determine whether more support is needed. Severe or persistent vomiting or signs of significant dehydration require prompt medical attention.
When appetite drops sharply, the makeup of meals matters more. Strategies worth raising with a clinician include:
Include protein in every meal and snack
Eat smaller, more frequent meals if full portions are difficult
Choose low-volume, nutrient-dense foods
Sip fluids throughout the day, separate from meals if necessary
Plan simple foods for days with higher nausea
Eat diverse foods for vitamins, minerals, and fiber
Ask if a nutritional supplement is appropriate
There's no single protein target that fits everyone, and needs vary, particularly for older adults and people managing kidney disease or other conditions. Individualized guidance from a clinician beats a number pulled off the internet.
Nutrition is only half of protecting muscle during weight loss. Resistance activity, which doesn't require heavy lifting, helps the body hold onto muscle: bands, light weights, chair exercises or body-weight movements, depending on ability. Anyone who is inactive or manages a health condition should check with a clinician first. Everyday function often says more than a body-composition number: rising from a chair, carrying groceries and climbing stairs without unusual fatigue.
Caregivers often notice reduced appetite first, especially in older adults, who already face gradual muscle loss with age. A person may not realize how little they're eating, especially if they're pleased with the weight loss itself. Watch for:
Unfinished meals or a refrigerator that isn't being restocked
Growing fatigue or difficulty preparing food
Reluctance to eat driven by nausea or early fullness
Asking "Are you able to eat enough to feel strong?" tends to open more useful discussion than commenting on weight lost.
GLP-1 medications remain valuable tools for treating obesity. The research on lean-tissue loss isn't an argument against using them. It's an argument for pairing treatment with real nutrition care and physical activity. A person doesn't have to be underweight to need help, and a lower number on the scale doesn't tell the whole story.
Explore Medtrition's website for practical information regarding product offerings to bridge the nutritional gaps often encountered in the GLP-1 journey.
Related Products
ProSource® Cup | ProSource® NoCarb | Gelatein®
Sources
American Society for Parenteral and Enteral Nutrition, Malnutrition Awareness Week
Mogna-Peláez, P., & Guasch-Ferré, M. (2026). Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care. The Journal of nutrition, 156(8), 101684. https://doi.org/10.1016/j.tjnut.2026.101684
Eisa, N., & Barood, O. (2026). Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, obesity & metabolism, 28(6), 4818–4827. https://doi.org/10.1111/dom.70666
Alissou, M., Demangeat, T., Folope, V., Van Elslande, H., Lelandais, H., Blanchemaison, J., Cailleaux, P. E., Guney, S., Aupetit, A., Aubourg, A., Rapp, C., Petit, A., Godin, M., Vignal, L., Grigioni, S., Déchelotte, P., Colange, G., Coëffier, M., & Achamrah, N. (2026). Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, obesity & metabolism, 28(1), 112–121. https://doi.org/10.1111/dom.70141